LOTTE BIOLOGICS Begins Full-Scale Operation of ADC Manufacturing Facility

- Signed a contract to manufacture an ADC therapeutic candidate for an Asia-based company 

- Marks the first order following the completion of LOTTE BIOLOGICS’ dedicated ADC manufacturing facility in March, signaling the official launch of its ADC CDMO business

[Photo] Ribbon-cutting ceremony at the ADC manufacturing facility on the Syracuse Bio Campus in New York

LOTTE BIOLOGICS (CEO James Park) announced on 24 that it has signed a manufacturing agreement with an Asia-based biotech company for the production of a clinical-stage ADC candidate.

This contract marks the first official step in the full-scale operation of the ADC manufacturing facility at the Syracuse Bio Campus in New York, which has been under expansion since 2023. With this, the company is launching its antibody-drug conjugate (ADC) contract development and manufacturing (CDMO) services, designed to meet a wide range of client needs from clinical development to commercial production. It also aims to further enhance the competitiveness of the Syracuse Bio Campus.

Building on this order, the company plans to pursue additional client acquisition opportunities while accelerating the expansion of partnerships to offer comprehensive one-stop services for ADC development and manufacturing. Through these efforts, LOTTE BIOLOGICS aims to strengthen its position in the ADC therapeutics market and further enhance its standing as a global CDMO.

LOTTE BIOLOGICS’ ADC manufacturing facility, built with an investment of approximately USD $100 million, is a cGMP-compliant site that offers end-to-end services. It features an integrated production and purification line, including a conjugation reactor with a capacity of up to 1,000 liters. The facility provides in-house quality control (QC) testing as well as advanced characterization services. In addition, it is equipped with a single-use system that supports the entire process; from antibody preprocessing to automated aseptic filling of drug substances; enabling flexible response to a wide range of client needs.

LOTTE BIOLOGICS’ CEO James Park stated, “With this contract as a starting point, we will ensure a stable supply of high-quality ADC therapeutics and solidify our position in the global market, not only as an antibody manufacturer, but also as a CDMO specializing in ADCs.” He added, “We also plan to actively pursue collaboration opportunities to further strengthen our competitiveness in the ADC modality business.

Meanwhile, LOTTE BIOLOGICS recently held a ribbon-cutting ceremony at its Syracuse Bio Campus in New York to celebrate the completion of its ADC manufacturing facility. The event was attended by approximately 100 people, including CEO James Park, Head of Global Strategy Yooyeol Shin, US General Manager Michael Hausladen, and employees from the Syracuse Bio Campus.

END